Future engagement strategies will be able to mediate the dynamic between the irreplaceable capabilities of humans and the extraordinary capabilities of AI, increasing the value of both.
Learn more and sign up here: https://t.co/56mkgxoahP
We’re launching our Pharmageddon Europe event this week, but not everyone’s going to like it. Read the Manifesto and join the waiting list here: https://t.co/bowvvGj8zy
#pharmageddon#impatienthealth
For those of you who haven't yet taken a few minutes to do the Impatient Healthcheck, now is your chance! This is the first time we've surveyed our database and I guarantee there will be some fascinating (possibly scary) insights for those who complete it. https://t.co/YDK6K3cwT2
Learn about the real future content management systems, from an ecosystem perspective and how to deliver rapid audience engagement, just as we’ve always wanted. Sign up: https://t.co/ANrYOUpQTi
MUSK RETURNS! Everyone will have the chance to comment and speak about some of the ideas presented. Mics are on! @elonmusk See you there? Register now! https://t.co/USmtXPF7v2
I’m excited to announce that Pharmageddon is coming to New York on June 11-12. Learn more about what’s in store here: https://t.co/GZjhoXx38x
#impatienthealth#pharmageddon#newyorkcity
The truth is, patient engagement has the potential to be much more. It’s not just about asking people what they think, it’s a holistic process that can reimagine our decision-making and value proposition.
Join my next webinar to learn more: https://t.co/GMZKvgReRF
We had nearly 2000 signups for the ‘Musk Pharma’ webinar yesterday. If you missed out, you can now grab the recording and a 50-page whitepaper right here:
https://t.co/ANlELnRuS1
I’d obviously love any feedback and thoughts about how to bring these ideas to life. @elonmusk#Musk
“No sales or marketing departments.” This has been Elon Musk’s approach to every company he has established so far. But would he go this far if he ran a big pharma company?
Only one way to find out: join our next webinar.
Find out more: https://t.co/Ur5FqzGx16
#Musk#ElonMusk
Join Paul Simms, Jenn Buechel, David Coman, and Stefanos Zenios as they take a different view of evolving #clinicaltrials. You might find it’s just the perspective you need.
Sign up now: https://t.co/JD44rMuQz2
A new generation of tools is changing how #fieldteams get educated on the #clinical value and learn to engage in the #hybrid landscape.
Sign up now to hear more: https://t.co/YmYtLGZ7WK
Join us for this free webinar with experts from #Biogen, #Amgen, and #ACTO to learn how others are tackling #DigitalTransformation for their teams: https://t.co/YmYtLGZ7WK
UK’s trailblazing AMR subscription model
It could see the UK pay up to £10 million annually for access to Pfizer’s and Shionogi’s products, regardless of how much is actually prescribed (https://t.co/gukartZsjx)
For more valuable insights, sign up here: https://t.co/l2wxYHxlnx
"#DigitalTransformation is not about the technology, it's about the people"
But are we developing the people?
The #technology for #learning & #development has made a big step up during the pandemic but it's time for an upgrade.
Sign up: https://t.co/YmYtLGZ7WK
What’s really happening in #clinicaltrials?
How much are #DCTs truly impacting key therapy areas, namely #Oncology, #Endocrinology, and #Cardiology? Is it all hype, are we resolutely traditional, or is it a mix of the two?
Take the survey now: https://t.co/xBBwLIkjRZ